Volume 7 Supplement 2

13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the Hungarian Society for Experimental and Clinical Pharmacology (MFT)

Open Access

The role of cannabinoid CB1 receptor agonists in gastric mucosal protection in rats and mice

  • Nashwan Shujaa1,
  • Zoltán S Zádori1,
  • Mahmoud Al-Khrasani1,
  • Susanna Fürst1,
  • Tibor Wenger2 and
  • Klára Gyires1Email author
BMC Pharmacology20077(Suppl 2):A47

https://doi.org/10.1186/1471-2210-7-S2-A47

Published: 14 November 2007

CB1 receptor agonists inhibit stimulated gastric acid secretion and exert an anti-ulcer activity in acid-dependent ulcer models. The aims of this study were to investigate the gastroprotective effect of cannabinoids in an acid-independent ulcer model and to analyze the role of opioid and vanilloid receptors in this effect. Gastric mucosal damage was induced by acidified ethanol in rats and in CB1+/+ and CB1-/- mice. Anandamide, methanandamide and WIN-55,212-2 inhibited the ethanol-induced gastric mucosal damage significantly after peripheral and central administration, and their effects were reversed by the CB1 receptor antagonist SR141716A. The gastroprotective effect of cannabinoid agonists was significantly decreased by naloxone and partially by capsazepine (TPRV1 receptor antagonist). The gastroprotective effect of opioid peptides DAGO and deltorphin II was significantly reduced in CB1-/- mice. In conclusion, cannabinoid CB1 receptors are likely to be involved in gastric mucosal defense. The effect seems to be central, and correlation between opioid and cannabinoid system in gastric mucosal protection may be raised.

Declarations

Acknowledgements

This work was supported by ETT 529/2006.

Authors’ Affiliations

(1)
Department of Pharmacology and Pharmacotherapy, Semmelweis University
(2)
Department of Human Morphology, Semmelweis University

Copyright

© Shujaa et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.

Advertisement